Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13223)	12/17/2003 1:42:21 PM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

<font color=green>Dimethaid Q3 Pennsaid sales to top $1.2-million (U.S.) 2003-12-17 11:36 MT - News Release An anonymous director reports DIMETHAID PROVIDES CORPORATE UPDATE Dimethaid Research has indicated that it expects second-quarter sales of its lead product Pennsaid to top $1.2-million (U.S.), representing a 70-per-cent increase over the previous quarter. The company also anticipates sales will continue growing throughout the remainder of the fiscal year. "We are extremely pleased with how well the marketplace has responded to Pennsaid," said Rebecca Keeler, president and chief executive officer of Dimethaid Research. Total revenue for the second quarter, ended Nov. 30, 2003, will exceed $1.4-million (U.S.). The company expects to report its second quarter results in mid-January. Business development To continue expanding worldwide Pennsaid sales, Dimethaid is also focusing on new business partnerships in countries where the product has received final approval. Negotiations are now under way with marketing and sales organizations in Finland, Greece, Iceland and Portugal. Cash management In November Dimethaid successfully completed a special warrant private placement, raising over $9.8-million (U.S.) in net proceeds. The company is effectively managing its cash position in light of the recent Provalis arbitration award, and will continue to take appropriate steps to conserve cash as Pennsaid sales ramp up in Canada, Italy and the United Kingdom. WARNING: The company relies upon litigation protection for "forward-looking" statements.